Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020230134 - ACSS2 INHIBITORS AND METHODS OF USE THEREOF

Publication Number WO/2020/230134
Publication Date 19.11.2020
International Application No. PCT/IL2020/050524
International Filing Date 14.05.2020
IPC
C07D 231/06 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
231Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
02not condensed with other rings
06having one double bond between ring members or between a ring member and a non-ring member
C07D 231/22 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
231Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
02not condensed with other rings
10having two or three double bonds between ring members or between ring members and non-ring members
14with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
18One oxygen or sulfur atom
20One oxygen atom attached in position 3 or 5
22with aryl radicals attached to ring nitrogen atoms
C07D 231/14 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
231Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
02not condensed with other rings
10having two or three double bonds between ring members or between ring members and non-ring members
14with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 231/38 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
231Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
02not condensed with other rings
10having two or three double bonds between ring members or between ring members and non-ring members
14with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
38Nitrogen atoms
C07D 213/56 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
213Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
02having three double bonds between ring members or between ring members and non-ring members
04having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
24with substituted hydrocarbon radicals attached to ring carbon atoms
54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
56Amides
C07D 233/66 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
233Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
54having two double bonds between ring members or between ring members and non-ring members
66with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Applicants
  • METABOMED LTD [IL]/[IL]
Inventors
  • NAKACHE, Philippe
  • EREZ, Omri
  • BOTTI, Simone
  • GOUTOPOULOS, Andreas
  • FINCH, Harry
Agents
  • COHEN, Mark S.
  • COHEN, Mark S.
Priority Data
16/411,16814.05.2019US
62/847,34814.05.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ACSS2 INHIBITORS AND METHODS OF USE THEREOF
(FR) INHIBITEURS D'ACSS2 ET LEURS PROCÉDÉS D'UTILISATION
Abstract
(EN)
The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral infection, alcoholism, alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), obesity/weight gain, anxiety, depression, post-traumatic stress disorder, inflammatory/autoimmune conditions and cancer, including metastatic cancer, advanced cancer, and dmg resistant cancer of various types.
(FR)
La présente invention concerne de nouveaux inhibiteurs d'ACSS2 ayant une activité dans la lutte contre le cancer, le traitement de l'alcoolisme, et l'infection virale (par exemple, CMV), une composition et des procédés de préparation de ceux-ci, ainsi que leurs utilisations dans le traitement d'une infection virale, de l'alcoolisme, la stéatohépatite alcoolique (ASH), la stéatohépatite non alcoolique (NASH), l'obésité/la prise de poids, l'anxiété, la dépression, le trouble de stress post-traumatique, les affections inflammatoires/auto-immunes et le cancer, y compris le cancer métastatique, le cancer avancé, et le cancer résistant aux médicaments de divers types.
Latest bibliographic data on file with the International Bureau